https://www.selleckchem.com/Androgen-Receptor.html
Stage II (node-positive) patients had better median OS compared to stage III (21 vs 4 months; p=0.00. 54.5% patients had recurrences, most commonly both systemic and nodal (45.83%). Median OS of patients without recurrences was 34 months. In this largest surgical series of AMs, outcome of stage III was significantly better than stage III and patients with stage II disease can have acceptable oncological outcomes. Radical surgical resections with or without lymphadenectomy could be considered in these patients. The role of adjuva
Like
Comment
Share
